RCEL Stock Overview
Operates as a regenerative medicine company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.20 |
| 52 Week High | US$18.93 |
| 52 Week Low | US$7.51 |
| Beta | 1.54 |
| 11 Month Change | 18.33% |
| 3 Month Change | 26.95% |
| 1 Year Change | -2.40% |
| 33 Year Change | -24.83% |
| 5 Year Change | -69.04% |
| Change since IPO | -51.20% |
Recent News & Updates
Recent updates
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Oct 04
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 18Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?
Jun 18Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding
Apr 12AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%
Feb 02The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%
Oct 20Avita Medical appoints James Corbett as CEO
Sep 29AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal
Sep 12Avita's burn therapy Recell gets insurance coverage in Japan following approval
Sep 01AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M
Aug 11AVITA Medical Is Interesting, But Not Just Yet
Dec 21AVITA Medical reports preliminary Q2 revenue in-line with consensus
Jan 12AVITA: COVID-19's Impact
Nov 17Shareholder Returns
| RCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.2% | 3.7% | 5.7% |
| 1Y | -2.4% | 29.2% | 36.9% |
Return vs Industry: RCEL underperformed the US Biotechs industry which returned 30.4% over the past year.
Return vs Market: RCEL underperformed the US Market which returned 36.3% over the past year.
Price Volatility
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RCEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RCEL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | www.avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
AVITA Medical, Inc. Fundamentals Summary
| RCEL fundamental statistics | |
|---|---|
| Market cap | US$313.30m |
| Earnings (TTM) | -US$57.32m |
| Revenue (TTM) | US$60.04m |
5.3x
P/S Ratio-5.6x
P/E RatioIs RCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCEL income statement (TTM) | |
|---|---|
| Revenue | US$60.04m |
| Cost of Revenue | US$8.61m |
| Gross Profit | US$51.43m |
| Other Expenses | US$108.75m |
| Earnings | -US$57.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 85.66% |
| Net Profit Margin | -95.47% |
| Debt/Equity Ratio | 348.0% |
How did RCEL perform over the long term?
See historical performance and comparison